RMi Pre-opening: Sticks and stones break bones

January 20, 2026 7:56am

But Greenland based words do hurt markets

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Pre-open Signals: 7 Negative with many non-pre-open indications; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t

US markets were closed Monday for a holiday; European and Asia-Pacific stocks were lower as traders reacted to U.S. President Trump’s threat to hike tariffs on European countries if they oppose his bid to buy Greenland.

RMi Closing Bell: Fuggily Friday … https://www.regmedinvestors.com/articles/14272

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249       

Tuesday: The pre-open Dow futures are DOWN -1.32% or (-656 points), the S&P futures are DOWN -1.46% or (-102 points) and the Nasdaq futures are DOWN -1.76% or (-453 points)

• U.S. stock futures tumble with intensified rhetoric on Greenland, Tuesday 1/20
• European markets sell off,
• Asia Pacific markets slid lower

Economic Data: None

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Monday was a market holiday
• Friday: The Dow closed DOWN -83.11 points or -0.17%, the S&P closed DOWN -4.46 points or -0.06% while the Nasdaq closed DOWN -14.634 points or -0.06%
• Thursday: The Dow closed UP +292.81 points or +0.60%, the S&P closed UP +17.87 points or +0.26% while the Nasdaq closed UP +58.272 points or +0.25%
• Wednesday: The Dow closed DOWN -42.24 points or -0.09%, the S&P closed DOWN -36.75 points or -0.53% while the Nasdaq closed DOWN -238.123 points or -1%
• Tuesday: The Dow closed DOWN -398.21 points or -0.80%, the S&P closed DOWN -13.53 points or -0.19% while the Nasdaq closed DOWN -24.032 points or -0.10%
• Last Monday: The Dow closed UP +86.13 points or +0.17%, the S&P closed UP +10.99 points or +0.16% while the Nasdaq closed UP +62,558 points or +0.26%

• Last week: The S&P 500 was down -0.4%, the Dow -0.3% and the Nasdaq was down -0.7%.
• The previous week: The S&P 500 was up +1.6%, the Dow +2.3% and the Nasdaq was up +1.9%.

Q1/26 – Q1 – 2 holiday,  3 negative and 3 positive closes  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Alnylam Pharmaceuticals (ALNY) closed down -$0.33 after Thursday’s -$7.53, Wednesday’s -$3.10, Tuesday’s -$0.95 and last Monday’s -$27.38 with a negative -$1.35 or -0.37% pre-open

BioNTech (BNTX) closed up +$2.93 after Thursday’s -$3.05, Wednesday’s +$1.93, Tuesday’s +$5.01 and last Monday’s +$2.33 with a negative -$2.49 or -2,28% pre-open

Moderna (MRNA) closed up +$2.48 after Thursday’s -$1.22 after Wednesday’s +$0.98 after Tuesday’s +$5.76 after Monday’s -$0.46 with a negative -$0.66 or -1.57% pre-open

Capricor Therapeutics (CAPR) up Friday +$0.31 after Thursday -$0.75, Wednesday’s flat, Tuesday’s +$0.28 and last Monday’s +$0.67 with a negative -$0.29 or -1.19% pre-open indication

• As CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!
• I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
• Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
• CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
• It has begun; timing will be everything!
• The higher CAPR rises, the steeper the fall!

Vertex (VRTX) closed up +$2.44 after Thursday’s -$10.61 after Wednesday’s -$5.14 after Tuesday’s -$5.92 after Monday’s -$3.27 with a negative -$2.40 or -0.54% pre-open

Ionis Pharmaceuticals (IONS) closed down -$0.88 after Thursday’s -$1.66, Wednesday’s -$0.61, Tuesday’s -$2.18 and last Monday’s +$1.36 with a negative -$1.33 or -1.74% pre-open

Beam Therapeutics (BEAM) closed down Friday -$0.83 after Thursday’s-$3.36, Wednesday’s +$0.86, Tuesday’s +$0.86 and last Monday’s +$6.14 with a negative -$0.70 or -2.24% pre-open

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, financings and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

• after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

January 3^rd Week:

• 1/19 – Monday was a holiday, MLK, Jr Day

January – 2nd week’s session

• 1/16 – Friday closed negative with 11 incliners, 28 decliners and 1 flat
• 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
• 1/7 – Wednesday closed positive with 33 incliners, 5 decliners and 2 flats
• 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
• 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

January 1st week:

• 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
• 1/1 -Thursday was a holiday, New Years Day

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in past session:   

• Last Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
• The previouys Monday: IQVIA Holdings (IQV), BioLife Solutions (BLFS), and Vericel (VCEL)

The worst three (3) in past session:

• Last Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)
• The previous Monday: Capricor Therapeutics (CAPR), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.